Conditions
Cutaneous Squamous Cell Carcinoma, Endometrial Cancer, Solid Tumor
Trial Purpose
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) [Cohort A] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) [Cohort B].
CLINICALTRIALS.GOV IDENTIFIER
NCT06036836
EU CT Number
2023-505022-34
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About the trial
All patients who enroll in the trial will receive medication while on the study.
Cutaneous Squamous Cell Carcinoma (cSCC) Patients
50% will receive MK-4280A (contains favezelimab and pembrolizumab) before and after surgery.
50% will receive pembrolizumab before and after surgery.
Endometrial Cancer (EC) Patients
50% will receive MK-4280A (contains favezelimab and pembrolizumab) and lenvatinib.
50% will receive pembrolizumab and lenvatinib.
Current trial phase
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date September 29, 2023
- Estimated primary completion date March 9, 2027
- Estimated trial completion date March 9, 2027
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about